Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea|
- Frequency of Adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]The frequency of adverse events by type, seriousness, time to onset, etc. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.
- Change from Baselin in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline and month 12 ] [ Designated as safety issue: No ]The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at month 12 relative to baseline.
- Change from Baselin in Fasting Blood Glucose [ Time Frame: Baseline and month 12 ] [ Designated as safety issue: No ]The change in the value of fasting blood glucose collected at month 12 relative to baseline.
|Study Start Date:||July 2011|
|Study Completion Date:||December 2014|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Aloglipin 25 mg, tablets, orally, once daily for up to 12 months
This is a special drug use surveillance on long-term use of alogliptin with a 1-year (12-month) observational period, designed to investigate the safety and efficacy of long-term combination therapy with alogliptin and sulfonylurea in patients with type 2 diabetes mellitus in a routine clinical setting.
Participants will be patients with type 2 diabetes mellitus who responded inadequately to treatment with sulfonylurea in addition to diet therapy and exercise therapy. The planned sample size is 1,000.
The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01964950
|Study Chair:||Postmarketing Group Manager||Takeda|